Lanreotide acetate
SIGMA/SML0132 - ≥98% (HPLC)
Synonym: 3-
CAS Number: 127984-74-1
Empirical Formula (Hill Notation): C54H69N11O10S2 · xC2H4O2
Molecular Weight: 1096.32 (free base basis)
Linear Formula: C54H69N11O10S2 · xC2H4O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C54H69N11O10S2.C2H4O2/ |
| InChI key | DEXPIBGCLCPUHE-HPDHVNDUSA |
| Quality Level | 100 ![]() |
| shipped in | wet ice |
| SMILES string | CC(O)=O.CC(C)[C@@H]1NC(=O |
| storage temp. | −20°C |
| Application: | Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice. |
| Biochem/physiol Actions: | Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors. |
| Biochem/physiol Actions: | Octapeptide somatostatin analog; sst2 somatostatin receptor agonist; Antineoplastic |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS08 |
| Signal word | Warning |
| Hazard statements | H361 |
| Precautionary statements | P281 |
| Hazard Codes | Xn |
| Risk Statements | 63 |
| Safety Statements | 36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |


